Targeted Antitumor Drugs: Monoclonal Antibodies by TargetMol

Targeted antitumor drugs are a class of therapies that use specific structural molecules on tumor tissues or cells as targets, and use certain antibodies and ligands that can specifically bind to these target molecules for direct or directed treatment purposes.

Targeted antitumor drugs can be divided into two categories: small molecule drugs and monoclonal antibodies.

In recent years, monoclonal antibody drugs have developed rapidly and gradually become the main direction of development in the field of biopharmaceuticals.

Monoclonal antibodies are antibodies secreted by B lymphocytes, which can only produce one proprietary antibody against one antigenic determinant cluster. Therefore, they have highly specific physicochemical properties, single biological activity, and strong specificity in binding to antigens. For this reason, it is also referred to as a „biological missile“, and most of the existing antibody drugs fall into this category.

Targeted antibodies have defined a new concept of „Tumor Therapy“ that involves a variety of tumor-related signaling pathways and targets, for example, in the treatment of solid tumors, the most commonly targeted proteins are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) and epidermal growth factor receptor- (HER/neu, or EGFR).

In recent years, immunotherapy has been one of the most prominent research methods in „Tumor Therapy“, and therefore „immune checkpoints“ have received much attention.

Immune checkpoints are sites that have an inhibitory effect on immune regulation during an immune response.

After the immune cells involved in the antitumor immune response are activated, the expression of various receptors on their surfaces are upregulated and bind to the corresponding ligands highly expressed on the surface of tumor cells, resulting in an inhibitory effect on the immune response and thus downregulating the intensity of the tumor-associated immune responses.

In the process of tumor occurrence and development, immunotherapy is used to enhance the immune function of the
body by inhibiting highly expressed immune checkpoint molecules and restoring the recognition ability of T cells, thereby
clearing or slowing down the progression of tumors.

The programmed death (PD-1 ) receptor and PD-1 /PD-L1 inhibitors are particularly notable among immunotherapies.

To date, several PD-1/PD-L1 antibodies have been marketed, such as Avelumab, Nivolumab, and Pembrolizumab, and have thus become the star products of recent years.

PD-1/PD-L1 inhibitors are also known as immune checkpoint inhibitors.

During tumorigenesis, tumor cells use PD-L1 to bind to PD-1 of T cells, „deceive“ T cells, evade T cell recognition, and continue to damage the body.

PD-L1/PD-1 antibodies can help T cells restore their ability to recognize and kill tumor cells by unmasking them from their camouflage. The most widely studied and used immune checkpoint inhibitors are PD-1, PD-L1 and CTLA-4 inhibitors.

Cat. No.	Products	CAS Number	Targets	Size
T9901	Adalimumab	331731-18-1	NF-α	5mg
T9902	Atezolizumab	1380723-44-3	HPD-L1	5mg
T9903	Avelumab	1537032-82-8	PD-L1	5mg
T9904	Bevacizumab	216974-75-3	VEGF	5mg
T9905	Cetuximab	205923-56-4	EGFR	5mg
T9906	Ipilimumab	477202-00-9	CTLA-4	5mg
T9907	Nivolumab	946414-94-4	PD-1/PD-L1 Interaction	5mg
T9908	Pembrolizumab	1374853-91-4	PD-1	5mg
T9909	Pertuzumab	380610-27-5	HER2	5mg
T9910	Rituximab	174722-31-7	CD20	5mg
T9911	Tocilizumab	375823-41-9	IL-6R	5mg
T9912	Trastuzumab	180288-69-1	HER2	5mg
T9913	Ustekinumab	815610-63-0	IL-12,IL-23	5mg
T9914	Vedolizumab	943609-66-3	Integrin	5mg
T9915	Eculizumab	219685-50-4	Complement Protein C5	5mg
T9916	Alirocumab	1245916-14-6	PCSK9	5mg
T9917	Denosumab	615258-40-7	RANK Ligand	5mg
T9918	Daratumumab	945721-28-8	CD38	5mg
T9919	Alemtuzumab	216503-57-0	CD52	5mg
T9920	Evolocumab	1256937-27-5	PCSK9	5mg
T9921	Infliximab	170277-31-3	TNF-α	5mg
T9922	Matuzumab	339186-68-4	EGFR	5mg
T9923	Nimotuzumab	828933-51-3	EGFR	5mg
T9924	Obinutuzumab	949142-50-1	CD20	5mg
T9924	Obinutuzumab	949142-50-1	CD20	5mg
T9926	Omalizumab	242138-07-4	IgE	5mg
T9926	Omalizumab	242138-07-4	IgE	5mg
T9928	Ranibizumab	347396-82-1	VEGF	5mg
T9929	Ramucirumab	947687-13-0	VEGFR2	5mg
T9930	Secukinumab	875356-43-7	IL17A	5mg
T11126	Durvalumab	1428935-60-7	PD-L1/PD-1	5mg

Check out more interesting articles here.